Kineta announced that TuHURA Biosciences is exercising its right to extend their exclusivity and right of first offer agreement for Kineta’s Vista blocking antibody KVA12123. Under the terms of the agreement entered in July between Kineta and TuHURA, TuHURA has the right to extend their rights for up to two 10-day periods. Kineta is entitled to receive $150,000 for each 10-day extension. On July 8, Kineta announced that it had entered into the agreement with TuHURA, a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. As part of the agreement, Kineta received a $5M nonrefundable payment from TuHURA in July. Under the terms of the agreement, any payment made by TuHURA in consideration for Kineta’s compliance with its obligations set forth in the agreement will be credited to the upfront payment from TuHURA if a transaction between the parties is completed. In August, Kineta announced that in collaboration with TuHURA, it reopened enrollment in the VISTA-101 clinical trial. Kineta and TuHURA continue to collaborate on the ongoing Phase 1 clinical program for patients with advanced solid tumor cancer.